Skip to content

Technology
Pipeline
About Us
News
Investors
Contact

Technology
Pipeline
About Us
News
Investors
Contact

Press Releases

news hero image

Choose Year
Search Press Releases

Found 33 Results

September 29, 2026

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron

September 14, 2026

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

September 8, 2026

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

August 19, 2026

Nasus Pharma Announces Transition of Chief Financial Officer

August 17, 2026

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update

July 28, 2026

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O’Grady as Chief Executive Officer to Lead Strategic Growth

June 22, 2026

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum

June 9, 2026

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)

12 3 4 5 »

IR Contact

Mike Moyer
LifeSci Advisors
617-308-4306
IR@nasuspharma.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Unsubscribe

Loading...

Science

Technology
Pipeline
NS003 Ondansetron
NS002 Epinephrine
NS001 Naloxone
Publications

Company

About us
Leadership
Board of Directors
Advisory Board
Contact

Investors

Investors Overview
Press Releases
Events
SEC Filings
Company Reports
Corporate Governance
Stock Information
Investor FAQs

© 2026 Nasus Pharma All rights reserved

Accessibility Statement
Cookies Policy
Privacy Policy
Terms And Conditions Of Use

Scroll to Top